Literature DB >> 25138048

Targeting primary mediastinal B-cell lymphoma.

Simon D Wagner1.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25138048      PMCID： PMC4196141          DOI： 10.18632/oncotarget.2351

Source DB:  PubMed          Journal:  Oncotarget        ISSN： 1949-2553


× No keyword cloud information.
  7 in total

1.  A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

Authors:  Leandro C Cerchietti; Alexandru F Ghetu; Xiao Zhu; Gustavo F Da Silva; Shijun Zhong; Marilyn Matthews; Karen L Bunting; Jose M Polo; Christophe Farès; Cheryl H Arrowsmith; Shao Ning Yang; Monica Garcia; Andrew Coop; Alexander D Mackerell; Gilbert G Privé; Ari Melnick
Journal:  Cancer Cell       Date:  2010-04-13       Impact factor: 31.743

2.  Cooperative epigenetic modulation by cancer amplicon genes.

Authors:  Lixin Rui; N C Tolga Emre; Michael J Kruhlak; Hye-Jung Chung; Christian Steidl; Graham Slack; George W Wright; Georg Lenz; Vu N Ngo; Arthur L Shaffer; Weihong Xu; Hong Zhao; Yandan Yang; Laurence Lamy; R Eric Davis; Wenming Xiao; John Powell; David Maloney; Craig J Thomas; Peter Möller; Andreas Rosenwald; German Ott; Hans Konrad Muller-Hermelink; Kerry Savage; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Dennis D Weisenburger; Wing C Chan; Randy D Gascoyne; David Levens; Louis M Staudt
Journal:  Cancer Cell       Date:  2010-12-14       Impact factor: 31.743

3.  POZ-, AT-hook-, and zinc finger-containing protein (PATZ) interacts with human oncogene B cell lymphoma 6 (BCL6) and is required for its negative autoregulation.

Authors:  Raffaela Pero; Dario Palmieri; Tiziana Angrisano; Teresa Valentino; Antonella Federico; Renato Franco; Francesca Lembo; Andres J Klein-Szanto; Luigi Del Vecchio; Donatella Montanaro; Simona Keller; Claudio Arra; Vasiliki Papadopoulou; Simon D Wagner; Carlo M Croce; Alfredo Fusco; Lorenzo Chiariotti; Monica Fedele
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

4.  Control of inflammation, cytokine expression, and germinal center formation by BCL-6.

Authors:  A L Dent; A L Shaffer; X Yu; D Allman; L M Staudt
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

5.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

6.  STAT6-mediated BCL6 repression in primary mediastinal B-cell lymphoma (PMBL).

Authors:  Olga Ritz; Karolin Rommel; Karola Dorsch; Elena Kelsch; Julia Melzner; Michaela Buck; Karen Leroy; Vasiliki Papadopoulou; Simon Wagner; Ralf Marienfeld; Silke Brüderlein; Jochen K Lennerz; Peter Möller
Journal:  Oncotarget       Date:  2013-07

7.  Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.

Authors:  Marie-Therese Häberle; Elena Kelsch; Karola Dorsch; Peter Möller; Olga Ritz
Journal:  Oncoscience       Date:  2014-04-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.